Skip to main content
. Author manuscript; available in PMC: 2022 Dec 29.
Published in final edited form as: ACS Appl Mater Interfaces. 2021 Dec 16;13(51):60852–60864. doi: 10.1021/acsami.1c16126

Figure 2.

Figure 2.

In vitro biocompatibility of CeONP. Cell viability of HepG2, Renca, SVEC4-10, and RAW264.7 after 24 h of CeONP treatment normalized to no treatment group (mean ± SD; n = 12; *p < 0.05).